AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

Courtesy of Smith Collection/Gado/Getty Images

Business

AbbVie Half Breaks Up with Alector on Alzheimer’s

In a filing with the SEC, Abbvie’s decision to terminate came after the two firms jointly conducted a review of their next steps for the drug.

July 8, 2022

2 min read

Vanessa Doctor, RN

Policy

AbbVie’s Tax Structure in Crosshairs of Senate Finance Committee Report

A Senate Finance Committee report shows the majority of AbbVie’s income is taxed through foreign subsidiaries, allowing the company to pay less than half the U.S. corporate tax rate.

July 7, 2022

3 min read

Alex Keown

Deals

PwC Projects ‘Flurry of Deals’ Across Life Science Industry

A new report by PwC projects that the second half of this year will see a “flurry of deals activity across all areas of the sector.”

June 24, 2022

3 min read

Mark Terry

Policy

AbbVie Redeems Priority Review Voucher for Rinvoq Approval

AbbVie has redeemed a Rare Pediatric Disease Priority Review Voucher for Rinvoq (upadactinib), following its FDA approval for adults with moderately to severely active ulcerative colitis in March.

June 23, 2022

3 min read

Mark Terry

SKYRIZI is the new option for psoriatic arthritis.

Drug Development

AbbVie Seeks New Indication for Migraine Drug Qulipta, Drops Deal with Morphic

AbbVie filed a supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval for Qulipta for the preventative treatment of migraine.

June 22, 2022

3 min read

Alex Keown

Drug Development

AbbVie’s Skyrizi Becomes First FDA-Approved IL-23 Inhibitor for Crohn’s Disease

The FDA’s decision is based on positive results from two induction and one maintenance clinical study of AbbVie’s Skyrizi for Crohn’s disease.

June 20, 2022

2 min read

Vanessa Doctor, RN

Drug Development

Clinical Catch-Up: AbbVie and Genmab, Intra-Cellular, Sanofi and GSK

Genmab and AbbVie announce positive data in large b-cell lymphoma, Intra-Cellular’s bipolar depression candidate hits the endpoint in Phase III and more.

June 17, 2022

6 min read

Mark Terry

Drug Development

AbbVie & Genmab EHA Data Indicate LBCL Drug Could Fill Unmet Need

Genmab’s Phase II expansion cohort of the EPCORE NHL-1 clinical trial revealed that its investigational bispecific antibody epcoritamab induced a durable response in patients with LBCL.

June 13, 2022

2 min read

Tristan Manalac

Business

AbbVie Touts New Data for Rare Blood Cancer & Leukemia Treatments

AbbVie announced Friday that its investigational drug navitoclax, when used together with ruxolitinib, eases symptoms in myelofibrosis patients who had not yet been treated with a JAK inhibitor.

June 10, 2022

2 min read

Tristan Manalac

JOBS